#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Retinal dystrophy Hereditary angioedema with C1 esterase inhibitor deficiency Kaposi's sarcoma Lymphatic malformation Burkitt's lymphoma Thyroid cancer metastatic Anal cancer recurrent Arrhythmogenic right ventricular dysplasia Mucous membrane pemphigoid Follicular lymphoma stage III Hypereosinophilic syndrome Multiple system atrophy Hypotransferrinaemia Hepato-lenticular degeneration Penile squamous cell carcinoma More trials…

    Learn about Rare Diseases

    Primary mediastinal large B-cell lymphoma Progressive multifocal leukoencephalopathy – Basic Information MELAS syndrome Fragile X syndrome – Basic Information Primary biliary cholangitis – Diagnostics Adrenocortical carcinoma – Life with Disease Cystic fibrosis – Basic Information Pleomorphic leiomyosarcoma – Diagnostics Propionic acidaemia – Diagnostics Synovial sarcoma recurrent More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Doxecitine Codeine Phosphate Desflurane Mirtazapine Capivasertib ABY-271 Tovorafenib TETRODOTOXIN Pralatrexate Triptorelin Acetate Fluorometholone Pyridoxine Hydrochloride Lixudebart Verapamil Hydrochloride Somapacitan Placebo Metformin Embonate Zilovertamab Vedotin TRIMIPRAMINE MALEATE Methoxsalen More therapies…

    Learn about Your Condition

    Menopause Tubulointerstitial nephritis Intervertebral disc protrusion Mantle cell lymphoma stage IV Glomerulonephritis chronic Atopic keratoconjunctivitis Hypoxia Cervix carcinoma stage I Acquired ATTR amyloidosis Neuropathy peripheral Major depression Peripheral artery stenosis Malignant fibrous histiocytoma Alpha-1 antitrypsin deficiency Coronary artery dissection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Diffuse large B-cell lymphoma refractory

  • Study of Rituximab, Gemcitabine, Dexamethasone, and Platinum with or without Selinexor for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Not recruiting

    4 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma recurrent
    • Diffuse large B-cell lymphoma refractory
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Dexamethasone
    Italy Poland Spain

  • Study on the Safety and Tolerability of Epcoritamab with Drug Combination for Patients with B-cell Non-Hodgkin Lymphoma

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Epcoritamab
    • Golcadomide
    • Ibrutinib
    Czechia Denmark France Germany Hungary The Netherlands +1

  • Study Comparing Polatuzumab Vedotin with Rituximab, Ifosfamide, Carboplatin, and Etoposide for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma
    • B-cell lymphoma
    • Diffuse large B-cell lymphoma refractory
    Investigated Drugs:
    • Etoposide Phosphate
    • Carboplatin
    • Etoposide
    Austria Germany Spain

  • Study on the Safety and Effectiveness of Polatuzumab Vedotin with Rituximab, Gemcitabine, and Oxaliplatin for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma refractory
    Investigated Drugs:
    • Gemcitabine Hydrochloride
    • Oxaliplatin
    • Polatuzumab Vedotin
    France Germany Greece Italy Spain

  • Study on Brentuximab Vedotin, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Brentuximab Vedotin
    • Lenalidomide
    • Rituximab
    Belgium Czechia Denmark France Italy Poland +1

  • Study of Mosunetuzumab and Polatuzumab Vedotin Combination Treatment in Patients with B-Cell Non-Hodgkin Lymphoma

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Follicular lymphoma
    • Diffuse large B-cell lymphoma
    • Diffuse large B-cell lymphoma recurrent
    Investigated Drugs:
    • Benzocaine
    • Rasburicase
    • Fludeoxyglucose (18F)
    Belgium Spain
Previous Page
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!